MedTrace Logo

Effects of Exogenous Ketosis on Proteinuria and Renal Function

NCT06867471 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2025-03-10

No results posted yet for this study

Summary

A randomized, placebo-controlled, double-blinded crossover study will be conducted. Fourteen patients with polycystic kidney disease (PKD) and 29 patients with proteinuric kidney disease will receive ketone bodies (Ketone-IQ) and placebo in a randomized order. Each treatment period is four weeks. There will be a wash-out period of two weeks in between treatment periods. Effect variables will be measured in the last day of each treatment period.

Conditions

  • Renal Insufficiency, Chronic
  • Polycystic Kidney Diseases
  • Proteinuria
  • Ketosis

Interventions

DIETARY_SUPPLEMENT

Ketone Diol, R-1,3-butanediol (Ketone-IQ)

Effect variables will be measured on the last day of treatment with Ketone-IQ

OTHER

Placebo drink

Effect variables will be measured on the last day of treatment with Placebo

Sponsors & Collaborators

  • Gødstrup Hospital

    lead OTHER

Principal Investigators

  • Trine Z Lyksholm, MD · University Clinic in Nephrology and Hypertenion, Godstrup Region Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-11
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06867471 on ClinicalTrials.gov